Recent Finacing
Recent Raise
DeuteRx develops deuterium-enabled chiral switching to create stabilized single-enantiomer small molecules; lead DRX-065 (deuterated R‑pioglitazone) with pipeline targeting NASH, oncology, sickle cell, and CNS disorders.
Focus Areas
Total Raised
Funding round